ClinicalTrials.gg
RecruitingNCT07591246Updated May 15, 2026

Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction

An interventional study of physical exercise program and usual care in Polycystic Ovary Syndrome, Non-Alcoholic Fatty Pancreatic Disease and Subclinical hypothyroïdism, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Polycystic Ovary Syndrome by Cairo University — 10 open to participants now, 10 under way, none of them phase 3. Polycystic Ovary Syndrome · Cairo University.

Planned enrollment
17th of 26
40 · median 55
Started
2026
with 3 others
No phase
20 of 34
10 open now
Registered
32nd of 34
by date

Among the 34 studies in Polycystic Ovary Syndrome by Cairo University, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2026, is one of 20 with no phase, and was the 32nd registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

10 of the 34 studies in Polycystic Ovary Syndrome by Cairo University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Polycystic Ovary Syndrome by Cairo University, or all of them as a file.
02

Study summary

females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)

Read the detailed description

females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism) will be divided to groups (twenty female for the group). groups will be treated with levothyroxine and metformin, but one of these groups will perform aerobic treadmill walking.

03

Conditions studied

  • Polycystic Ovary Syndrome
  • Non-Alcoholic Fatty Pancreatic Disease
  • Subclinical hypothyroïdism
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PCOS
  • fattty pancrease (non-alcoholic)
  • subclinical hypothyroid (signifcant with thyroid stimauted horomone more than 10 mIU/L) and normal non-disordered free thyroxine horomones

Exclusion criteria

Exclusion Criteria:

  • cardiac disesase
  • renal diseases
  • respiratory disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    group number 1

    twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month.

    Behavioral: physical exercise program

  • Active comparator
    group number 2

    twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin for six month

    Other: usual care

Interventions

  • Behavioralphysical exercise program

    twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month.

  • Otherusual care

    twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily two times of 500-mg metformin for six month.

06

What researchers measure

Primary outcomes

  1. Dehydroepiandrosterone

    it is a hormone involved in synthesis of sex hormones

    Time frame: it will be measured after 6 months

Secondary outcomes

  1. ratio of leutinzing hromone to hormone of follicels stimulatting hormones

    this ration express level of sex hormone

    Time frame: it will be measured after 6 months

  2. testesterone

    it is a sex horomone

    Time frame: it will be measured after 6 months

  3. body mass index

    it will be assessed on empty stomach and bladder

    Time frame: it will be measured after 6 months

  4. waist circumference

    it will be assessed on umblical levels

    Time frame: it will be measured after 6 months

  5. blood gluocose

    it will be assessed in fasting status

    Time frame: it will be measured after 6 months

  6. glycated hemoglubin

    it is an indiactor for longterm satus of blood gloucose

    Time frame: it will be measured after 6 months

  7. insulin

    it will be assessed in plasma

    Time frame: it will be measured after 6 months

  8. thyroid stimualtined horomone

    it will be assessed in plasma

    Time frame: it will be measured after 6 months

  9. triglyceridess

    it will be assessed in plasma

    Time frame: it will be measured after 6 months

  10. low densitiy liopporotein

    it will be assessed in plasma

    Time frame: it will be measured after 6 months

  11. cholesteroll

    it will be assessed in plasma

    Time frame: it will be measured after 6 months

  12. high densitiy lipoporteins

    it will be assessed in plasma

    Time frame: it will be measured after 6 months

  13. alanine transaminase

    it will be assessed in plasma

    Time frame: it will be measured after 6 months

  14. aspartatte transaminase

    it will be assessed in plasma

    Time frame: it will be measured after 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 9 months is below that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2026
First posted
May 15, 2026
StartActual
Mar 7, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07591246
Lead sponsor
Cairo University
Responsible party
Ali Mohamed Ali ismail (lecturer of physical therapy for Cardiovascular, Respiratory disorder and Geriatrics, Faculty of Physical Therapy, Cairo University, Cairo University) — Principal investigator
First posted
May 15, 2026
Start date
Mar 7, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 15, 2026

Study contacts

Ali MA Ismail, lecturer
Contact
ali.mohamed@pt.cu.edu.eg
01005154209
ali mohamed
Contact
allooka2012@gmail.com
01031321109
Ali MA Ismail, lecturer
principal investigator · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion